William Blair Reaffirms Outperform Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

William Blair reaffirmed their outperform rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report sent to investors on Thursday morning, RTT News reports.

Several other equities analysts also recently commented on the stock. Barclays lowered their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating on the stock in a research report on Thursday. HC Wainwright reissued a buy rating and set a $8.00 target price on shares of Barinthus Biotherapeutics in a research report on Friday, June 7th.

Barinthus Biotherapeutics Price Performance

Barinthus Biotherapeutics stock opened at $1.83 on Thursday. The company has a market capitalization of $71.42 million, a price-to-earnings ratio of -0.99 and a beta of -0.46. Barinthus Biotherapeutics has a one year low of $1.64 and a one year high of $5.10. The company’s fifty day moving average price is $2.35 and its two-hundred day moving average price is $2.73.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Monday, May 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.24. As a group, sell-side analysts anticipate that Barinthus Biotherapeutics will post -2.3 earnings per share for the current year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. DC Funds LP purchased a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 642,204 shares of the company’s stock, valued at approximately $1,528,000. Barinthus Biotherapeutics comprises 14.8% of DC Funds LP’s investment portfolio, making the stock its 3rd biggest holding. DC Funds LP owned about 1.65% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.